<p>（RTTNews）- Q32 Bio Inc.（QTTB）在公司宣布与一组新老机构投资者达成 5500 万美元的私募融资后，股价上涨。</p>
<p>公司表示已签署证券购买协议，以每股 8.00 美元的价格出售 672.5 万股普通股，以及 150,000 个预先融资的认股权证，每个认股权证的价格为 7.9999 美元，相当于股价减去 0.0001 美元的行使价格。预先融资的认股权证可立即行使，并在完全行使之前保持有效。</p>
<p>Q32 Bio 预计在扣除费用和支出之前将获得约 5500 万美元的总收益，融资预计于 2026 年 5 月 28 日完成，需满足惯例的交割条件。本轮融资由 BVF Partners L.P.主导，RA Capital Management、OrbiMed 和 Atlas Venture 参与。摩根士丹利担任主承销商，奥本海默公司担任承销商。</p>
<p>公司指出，此次发行为私募，意味着证券是在不涉及公开发行的交易中出售的，并且未注册股份的转售及预先融资认股权证所对应的股份。</p>
<p>Q32 Bio 正在推进两个主要项目：Bempikibart（ADX-914），一种完全人源的 IL-7 受体拮抗剂，正在评估用于自身免疫和炎症性疾病；以及 ADX-097，一种靶向组织的补体抑制剂，旨在调节补体系统的过度激活。这两个项目均处于临床开发阶段，代表了公司对精准免疫学的关注。</p>
<p>QTTB 在过去一年内的交易区间为 1.35 美元至 13.00 美元。目前股价为 11.64 美元，上涨 64.46%。</p>
<p>此处表达的观点和意见仅代表作者的观点，并不一定反映纳斯达克公司的观点。</p>

QTTB

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

<p>(RTTNews) - Q32 Bio Inc. (QTTB) 的股价上涨，此前公司宣布与一组新老机构投资者达成 5500 万美元的私募融资</p>

<p>(RTTNews) - Q32 Bio Inc. (QTTB) is trading higher after the company announced a $55 million private placement financing with a group of new and existing institutional investors.</p>
<div class="lb-trans"><p>（RTTNews）- Q32 Bio Inc.（QTTB）在公司宣布与一组新老机构投资者达成 5500 万美元的私募融资后，股价上涨。</p>
</div><p>The company said it has entered into a securities purchase agreement to sell 6.725 million shares of common stock at $8.00 per share, along with 150,000 pre-funded warrants priced at $7.9999 each, equal to the share price minus the $0.0001 exercise price. The pre-funded warrants are immediately exercisable and remain outstanding until fully exercised.</p>
<div class="lb-trans"><p>公司表示已签署证券购买协议，以每股 8.00 美元的价格出售 672.5 万股普通股，以及 150,000 个预先融资的认股权证，每个认股权证的价格为 7.9999 美元，相当于股价减去 0.0001 美元的行使价格。预先融资的认股权证可立即行使，并在完全行使之前保持有效。</p>
</div><p>Q32 Bio expects to receive approximately $55 million in gross proceeds before fees and expenses, with the financing scheduled to close on May 28, 2026, subject to customary closing conditions. The round is being led by BVF Partners L.P., with participation from RA Capital Management, OrbiMed, and Atlas Venture. Morgan Stanley acted as lead placement agent and Oppenheimer &amp; Co. acted as a placement agent.</p>
<div class="lb-trans"><p>Q32 Bio 预计在扣除费用和支出之前将获得约 5500 万美元的总收益，融资预计于 2026 年 5 月 28 日完成，需满足惯例的交割条件。本轮融资由 BVF Partners L.P.主导，RA Capital Management、OrbiMed 和 Atlas Venture 参与。摩根士丹利担任主承销商，奥本海默公司担任承销商。</p>
</div><p>The company noted that the offering was conducted as a private placement, meaning the securities were sold in a transaction not involving a public offering and are not register the resale of the shares and the shares underlying the pre-funded warrants.</p>
<div class="lb-trans"><p>公司指出，此次发行为私募，意味着证券是在不涉及公开发行的交易中出售的，并且未注册股份的转售及预先融资认股权证所对应的股份。</p>
</div><p>Q32 Bio is advancing two lead programs: Bempikibart (ADX-914), a fully human IL-7 receptor antagonist being evaluated in autoimmune and inflammatory diseases, and ADX-097, a tissue-targeted complement inhibitor designed to regulate overactivation of the complement system. Both programs are in clinical development and represent the company's focus on precision immunology.</p>
<div class="lb-trans"><p>Q32 Bio 正在推进两个主要项目：Bempikibart（ADX-914），一种完全人源的 IL-7 受体拮抗剂，正在评估用于自身免疫和炎症性疾病；以及 ADX-097，一种靶向组织的补体抑制剂，旨在调节补体系统的过度激活。这两个项目均处于临床开发阶段，代表了公司对精准免疫学的关注。</p>
</div><p>QTTB has traded between $1.35 and $13.00 over the past year. The stock is currently trading at $11.64, up 64.46%.</p>
<div class="lb-trans"><p>QTTB 在过去一年内的交易区间为 1.35 美元至 13.00 美元。目前股价为 11.64 美元，上涨 64.46%。</p>
</div><p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
<div class="lb-trans"><p>此处表达的观点和意见仅代表作者的观点，并不一定反映纳斯达克公司的观点。</p>
</div>

Q32 Bio Raises $55 Million In Private Placement; Stock Up

nasdaq

Q32 Bio

摩根士丹利

奥本海默控股

纳斯达克 OMX 交易所

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Q32 Bio 通过私募融资筹集了 5500 万美元；股价上涨